Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
2000 1
2001 1
2004 1
2005 8
2006 27
2007 37
2008 78
2009 139
2010 166
2011 177
2012 227
2013 297
2014 259
2015 302
2016 278
2017 230
2018 251
2019 228
2020 251
2021 241
2022 205
2023 172
2024 69

Text availability

Article attribute

Article type

Publication date

Search Results

3,132 results

Results by year

Filters applied: . Clear all
Page 1
Prasugrel-related hepatotoxicity.
Dogan Z, Yurtdas M, Bektasoglu G. Dogan Z, et al. J Pak Med Assoc. 2022 Nov;72(11):2295-2297. doi: 10.47391/JPMA.3179. J Pak Med Assoc. 2022. PMID: 37013306 Free article.
Little is known about Prasugrel-induced hepatotoxicity, although mild-to-moderate alanine transaminase (ALT) and gamma glutamyl transpeptidase (GGT) elevations have been noticed in post-marketing surveillance. Herein, we report the case of a patient with Prasugrel-r …
Little is known about Prasugrel-induced hepatotoxicity, although mild-to-moderate alanine transaminase (ALT) and gamma glutamyl trans …
Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis.
Shah RP, Shafiq A, Hamza M, Maniya MT, Duhan S, Keisham B, Patel B, Alamzaib SM, Yashi K, Uppal D, Sattar Y, Tiwari D, Paul TK, AlJaroudi W, Alraies MC. Shah RP, et al. Am J Cardiol. 2023 Nov 15;207:206-214. doi: 10.1016/j.amjcard.2023.08.117. Epub 2023 Sep 24. Am J Cardiol. 2023. PMID: 37751668 Review.
Limited data comparing prasugrel and ticagrelor in acute coronary syndrome are available. ...The overall mean age was 62.73 years, whereas the mean age for the ticagrelor and prasugrel groups was 63.80 and 61.65 years, respectively. Prasugrel is equally effec …
Limited data comparing prasugrel and ticagrelor in acute coronary syndrome are available. ...The overall mean age was 62.73 years, wh …
Prasugrel hydrochloride for the treatment of sickle cell disease.
Conran N, Rees DC. Conran N, et al. Expert Opin Investig Drugs. 2017 Jul;26(7):865-872. doi: 10.1080/13543784.2017.1335710. Epub 2017 Jun 12. Expert Opin Investig Drugs. 2017. PMID: 28562105 Review.
While this genetic disease is caused by hemoglobin polymerization, subsequent downstream events trigger platelet activation, vaso-occlusion and the disease's complex pathophysiology. Areas covered: The oral thienopyridine, prasugrel hydrochloride, irreversibly inhib …
While this genetic disease is caused by hemoglobin polymerization, subsequent downstream events trigger platelet activation, vaso-occlusion …
Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.
Gimbel M, Qaderdan K, Willemsen L, Hermanides R, Bergmeijer T, de Vrey E, Heestermans T, Tjon Joe Gin M, Waalewijn R, Hofma S, den Hartog F, Jukema W, von Birgelen C, Voskuil M, Kelder J, Deneer V, Ten Berg J. Gimbel M, et al. Lancet. 2020 Apr 25;395(10233):1374-1381. doi: 10.1016/S0140-6736(20)30325-1. Lancet. 2020. PMID: 32334703 Clinical Trial.
We aimed to investigate the safety and efficacy of clopidogrel compared with ticagrelor or prasugrel in older patients with non-ST-elevation acute coronary syndrome (NSTE-ACS). ...FINDINGS: Between June 10, 2013, and Oct 17, 2018, 1002 patients were randomly assigned to cl …
We aimed to investigate the safety and efficacy of clopidogrel compared with ticagrelor or prasugrel in older patients with non-ST-el …
Switching From Ticagrelor or Prasugrel to Clopidogrel.
Nawarskas JJ, Montoya TN. Nawarskas JJ, et al. Cardiol Rev. 2018 Mar/Apr;26(2):107-111. doi: 10.1097/CRD.0000000000000181. Cardiol Rev. 2018. PMID: 29215418 Review.
Ticagrelor and prasugrel are newer antiplatelet drugs which, like clopidogrel, block the P2Y12 platelet receptor to inhibit platelet aggregation. ...From a pharmacodynamic perspective, switching patients from ticagrelor or prasugrel to clopidogrel comes at a cost of …
Ticagrelor and prasugrel are newer antiplatelet drugs which, like clopidogrel, block the P2Y12 platelet receptor to inhibit platelet …
Prasugrel hydrochloride for the treatment of acute coronary syndrome patients.
Gunarathne A, Hussain S, Gershlick AH. Gunarathne A, et al. Expert Rev Cardiovasc Ther. 2016 Nov;14(11):1215-1226. doi: 10.1080/14779072.2016.1245145. Expert Rev Cardiovasc Ther. 2016. PMID: 27701930 Review.
Expert commentary: Prasugrel is an oral third-generation inhibitor of platelet activation and aggregation. Laboratory studies and early phase clinical trials show prasugrel has a faster onset of action, is more potent and has reduced inter-patient response variabili …
Expert commentary: Prasugrel is an oral third-generation inhibitor of platelet activation and aggregation. Laboratory studies and ear …
Prasugrel in the Elderly.
Bangalore S. Bangalore S. Circulation. 2018 Jun 5;137(23):2446-2449. doi: 10.1161/CIRCULATIONAHA.118.033952. Circulation. 2018. PMID: 29866773 No abstract available.
The Rationale for and Clinical Pharmacology of Prasugrel 5 mg.
Jakubowski JA, Erlinge D, Alexopoulos D, Small DS, Winters KJ, Gurbel PA, Angiolillo DJ. Jakubowski JA, et al. Am J Cardiovasc Drugs. 2017 Apr;17(2):109-121. doi: 10.1007/s40256-016-0202-3. Am J Cardiovasc Drugs. 2017. PMID: 27854064 Review.
Data from a prasugrel phase III study, TRITON-TIMI 38, suggested that a lower MD might be more suitable for patients weighing <60 kg or aged 75 years; subsequent pharmacokinetic and pharmacodynamic studies have indicated that prasugrel 5 mg reduced platelet react …
Data from a prasugrel phase III study, TRITON-TIMI 38, suggested that a lower MD might be more suitable for patients weighing <60 …
The role of prasugrel in the management of acute coronary syndromes: a systematic review.
Spartalis M, Tzatzaki E, Spartalis E, Damaskos C, Athanasiou A, Moris D, Politou M. Spartalis M, et al. Eur Rev Med Pharmacol Sci. 2017 Oct;21(20):4733-4743. Eur Rev Med Pharmacol Sci. 2017. PMID: 29131238 Free article. Review.
We have conducted a systematic review to retrieve current evidence regarding the role of prasugrel in the management of ACS. Evidence comparing prasugrel, clopidogrel, and ticagrelor remain scant. ...CONCLUSIONS: Prasugrel and ticagrelor are today the recomme …
We have conducted a systematic review to retrieve current evidence regarding the role of prasugrel in the management of ACS. Evidence …
Efficacy and safety of prasugrel therapy for intracranial aneurysms with endovascular treatment: A meta-analysis.
Xia P, He C, Chen L, Zou L, Sun S, Cui P, Wang W. Xia P, et al. J Neurol Sci. 2019 Feb 15;397:174-178. doi: 10.1016/j.jns.2019.01.005. Epub 2019 Jan 8. J Neurol Sci. 2019. PMID: 30641247 Review.
BACKGROUND: Prasugrel as a second generation P2Y12 adenosine diphosphate receptor antagonist which in the cerebral aneurysms with Endovascular treatment have become more emphasized. OBJECTIVE: To compare the efficacy and safety of prasugrel therapy for intracranial …
BACKGROUND: Prasugrel as a second generation P2Y12 adenosine diphosphate receptor antagonist which in the cerebral aneurysms with End …
3,132 results

Searches related to "prasugrel"